{"id":"NCT05062759","sponsor":"AstraZeneca","briefTitle":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Participants With Moderate to Severe Asthma (VECTOR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-23","primaryCompletion":"2022-03-21","completion":"2022-07-18","firstPosted":"2021-09-30","resultsPosted":"2023-04-21","lastUpdate":"2023-06-22"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Asthma"],"interventions":[{"type":"DRUG","name":"Tezepelumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tezepelumab","type":"EXPERIMENTAL"},{"label":"Placebo to Tezepelumab","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous \\[SC\\] every 4 weeks \\[Q4W\\]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the USA.","primaryOutcome":{"measure":"Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)","timeFrame":"From Week 12 to Week 16","effectByArm":[{"arm":"Tezepelumab","deltaMin":7.34,"sd":1.361},{"arm":"Placebo","deltaMin":4.75,"sd":1.455}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["38064153"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00031&amp;attachmentIdentifier=30f0d69f-126e-4f79-8bc8-0542f713c2b0&amp;fileName=D5180C00031_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["COVID-19","Acute sinusitis","Ear infection","Viral upper respiratory tract infection","Arthralgia"]}}